Journal of Vascular and Interventional Radiology最新文献

{"title":"Evolution of Renal Trauma Management: When Less is More.","authors":"Derek W Cool","doi":"10.1016/j.jvir.2026.109106","DOIUrl":"https://doi.org/10.1016/j.jvir.2026.109106","url":null,"abstract":"","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"109106"},"PeriodicalIF":3.1,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemorrhoidal Artery Embolization Involving a Median Sacral Artery Variant: A Case Series.","authors":"Ajay Varadhan, Mikin V Patel, Layth Alkhani, Marie Giordanino, Osman S Ahmed, Vincent Vidal","doi":"10.1016/j.jvir.2026.109115","DOIUrl":"https://doi.org/10.1016/j.jvir.2026.109115","url":null,"abstract":"","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"109115"},"PeriodicalIF":3.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact on renal function, tumor volume, and complications of transarterial embolization for renal angiomyolipomas: An Evidence-Based systematic review and meta-analysis.","authors":"Adriana Fudaba Orra, Soraya Hussein Orra, Juan Victor Nabhan Martinez, José Pinhata Otoch, José Arnaldo Shiomi da Cruz","doi":"10.1016/j.jvir.2026.109113","DOIUrl":"https://doi.org/10.1016/j.jvir.2026.109113","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the effect of transarterial embolization (TAE) on tumor burden, renal function, and safety in renal angiomyolipoma (AML), and to identify drivers of between-study heterogeneity.</p><p><strong>Materials and methods: </strong>Systematic review and meta-analysis following PRISMA and prospectively registered in PROSPERO (number on the title page). Major databases were searched through January 2024. Morphologic response was expressed as percentage reduction from baseline (random-effects ratio of means; medians converted by Wan's method); proportions were pooled by arcsine transformation. Risk of bias was assessed with ROBINS-I, RoB 2, and the JBI checklist.</p><p><strong>Results: </strong>Seventy-nine studies (1,798 patients) were included. TAE reduced tumor volume by 55.7% (95% CI, 49.3-61.3%; I² = 85.6%; k = 18) and diameter by 34.2% (95% CI, 29.1-38.9%; I² = 70.1%; k = 43). The interval to post-procedural imaging accounted for 50.7% of the between-study variance in volume reduction (P = .002); predicted reduction rose from 44% at 1 month to 63% at 36 months, a gradient three cohorts with serial imaging reproduced within-study. Serum creatinine and estimated glomerular filtration rate showed no clinically meaningful change from baseline. Pooled technical and clinical success were 98% and 97%; adverse events other than post-embolization syndrome occurred in 3%, and post-embolization syndrome in 46%.</p><p><strong>Conclusions: </strong>TAE achieves substantial, strongly time-dependent tumor reduction with high procedural success and few adverse events. Renal function was stable relative to baseline, but no included study used a surveillance comparator. Standardized outcome definitions and prespecified imaging intervals are needed before pooled estimates can guide patient selection.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"109113"},"PeriodicalIF":3.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Animal Models for Interventional Oncology Research: Overview and Considerations in the Era of New Approach Methodologies.","authors":"Ron C Gaba, Wali Badar, Kailey M Bell, Tanishka D Bhatt, Olayinka G David, Nusrat Khan, Sneha Mittal, Luke N Redlon Bms, Kyle M Schachtschneider, Lawrence B Schook, Taryi Wint, Lobna Elkhadragy","doi":"10.1016/j.jvir.2026.109112","DOIUrl":"https://doi.org/10.1016/j.jvir.2026.109112","url":null,"abstract":"<p><p>While translational animal models play a meaningful role in interventional oncology (IO) research, recent attention has focused on new approach methodologies (NAMs) prioritizing human biology-based paradigms. In this narrative review, animal models used in IO research, spanning mouse, rat, woodchuck, rabbit, pig, dog, and non-human primate platforms, are presented. In addition, \"next generation\" animal models, such as humanized models, genetically defined models, and comorbidity models, are summarized. Subsequently, NAM concepts, including organoids, organ-on-a-chip systems, ex vivo organ preparations, and artificial intelligence and in silico modeling tools, and their potential for advancing IO research, are described. Finally, the complementary value of preclinical models in the NAMs era and model selection are considered.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"109112"},"PeriodicalIF":3.1,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yttrium-90 Radioembolization for High-Risk Hepatocellular Adenomas: A Single-Institution Experience.","authors":"Nathan Ji, Alex Sher, Josh Kim, Bryan Pacheco, Brett Marinelli, Jenanan Vairavamurthy, Dan Shilo, Rajesh Patel, Rahul Patel, Vivian Bishay, Aaron Fischman, Francis Nowakowski, Robert Lookstein, Kirema Garcia-Reyes, Edward Kim","doi":"10.1016/j.jvir.2026.109114","DOIUrl":"https://doi.org/10.1016/j.jvir.2026.109114","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the safety and efficacy of Yttrium-90 (Y-90) transarterial radioembolization (TARE) for the treatment of high-risk hepatocellular adenomas (HCAs) at a single tertiary care center.</p><p><strong>Materials and methods: </strong>A retrospective review was performed of all patients who underwent TARE for HCAs at a tertiary care center between 2010 and 2025. Clinical, laboratory, imaging, and safety data were collected for twelve patients with 22 HCAs included in the study. The primary endpoint was treatment-related adverse events (AEs) graded by CTCAE and SIR AE classification. The secondary endpoints included target and overall radiologic response assessed by mRECIST.1 Patients were followed up with MRI at 6 weeks, 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months. Median follow-up between Y-90 and latest imaging was 17.7 months, with an IQR of 12.9 [8.0-20.9] months.</p><p><strong>Results: </strong>Indications for treatment included symptomatic adenoma (5%, 1/22), risk of malignant transformation (100%, 22/22) and hemorrhage risk (50%, 11/22). Grade 1 AEs (nausea, fatigue, anorexia, diarrhea, abdominal and shoulder pain) occurred in 75% (9/12) of patients. No grade 2 or greater AEs occurred. The objective response rate (ORR) was 100% (20/20) (complete target lesion response [CR]: 85% (17/20), partial target lesion response [PR]: 15% (3/20)). No lesions ruptured, progressed, or recurred during follow-up.</p><p><strong>Conclusion: </strong>In this single-institution experience, TARE was safe and demonstrated high short to intermediate-term ORRs in the treatment of high-risk hepatocellular adenomas. Larger prospective studies with longer duration of follow up are needed to confirm these findings.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"109114"},"PeriodicalIF":3.1,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous aortic thrombectomy with Inari ProTrieve Sheath and Penumbra Aspiration Catheter.","authors":"Jacqueline Figueroa, Andrew De Feria, Delaram Pourkalbassi, Jonathan Iglesias","doi":"10.1016/j.jvir.2026.109110","DOIUrl":"https://doi.org/10.1016/j.jvir.2026.109110","url":null,"abstract":"","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"109110"},"PeriodicalIF":3.1,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wireless Tenzing Crossing of Large Vessel-Occlusions - Feasibility of a Technique After Failed Stroke Thrombectomy with Traditional Approaches.","authors":"Faraz Behzadi, Kenneth Zurcher, Isabel L Bauer, Cameron M McDougall, Andrei V Alexandrov, Nikhil K Mehta","doi":"10.1016/j.jvir.2026.109109","DOIUrl":"https://doi.org/10.1016/j.jvir.2026.109109","url":null,"abstract":"<p><strong>Introduction: </strong>To test feasibility of Tenzingplasty as bailout technique for resistant large vessel occlusion (LVO). LVO is primarily treated with endovascular thrombectomy (EVT). Up to 10% of cases fail to achieve reperfusion, often due to resistant clot characteristics, intracranial atherosclerotic disease (ICAD), or technical challenges. This study presents a case-series evaluating a bailout crossing technique-wireless \"Tenzingplasty\" using the Tenzing delivery catheter-for failed conventional EVT approaches with aspiration catheters and microwire crossing.</p><p><strong>Methods: </strong>A retrospective review was performed between October 2025 and February 2026 at a single comprehensive stroke center, including adult patients who underwent EVT within 24 hours of stroke onset who had failed multiple aspiration and microwire crossing attempts. Wireless crossing with Tenzing catheter and subsequent Tenzingplasty was employed as a \"last hope\" technique to traverse and disrupt resistant occlusions in select cases (all cases included). Clinical, procedural, and outcome data were analyzed.</p><p><strong>Results: </strong>All five cases achieved successful clot disruption and reperfusion, with 60% attaining complete (TICI 3) recanalization. Two patients required adjunctive stenting due to re-occlusion risk. No intraoperative complications, including vessel dissection or perforation, were observed. One patient experienced an asymptomatic subarachnoid hemorrhage. Functional outcomes were favorable: 80% achieving a 90-day modified Rankin Scale (mRS) ≤2 and no mortality reported. Mean NIHSS improved post-procedure.</p><p><strong>Conclusion: </strong>This is a proof-of-concept case-series is a feasibility report that wireless Tenzingplasty may offer a rescue strategy for resistant LVO, particularly in cases involving ICAD or failed wire access. Larger, controlled studies are needed to validate its safety and broader applicability.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"109109"},"PeriodicalIF":3.1,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial Radioembolization for Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria: A Single-Center Retrospective Cohort Study.","authors":"Tae Wook Baek, Gun Ha Kim, Eunbyeol Ko, Jeongyeon Kim, Changhwan Sung, Hyo Jung Park, Sehee Kim, Hee Ho Chu, Jin Hyoung Kim, Dong Il Gwon","doi":"10.1016/j.jvir.2026.109108","DOIUrl":"https://doi.org/10.1016/j.jvir.2026.109108","url":null,"abstract":"<p><strong>Purpose: </strong>To describe clinical outcomes after transarterial radioembolization (TARE) for hepatocellular carcinoma (HCC) beyond the Up-to-Seven criteria.</p><p><strong>Materials and methods: </strong>This retrospective study included 94 treatment-naïve patients with HCC beyond the Up-to-Seven criteria who underwent TARE between November 2021 and December 2025. Outcomes included tumor response, local tumor progression-free survival (LTPFS), progression-free survival (PFS), overall survival (OS), and adverse events.</p><p><strong>Results: </strong>The median maximum tumor diameter was 9.5 cm (interquartile range, 7.1-11.4 cm). A single lesion was observed in 55 (58.5%) patients, 30 (31.9%) had oligonodular disease, and 9 (9.6%) had ≥5 lesions. Index-lesion complete response (CR) and objective response rate (ORR) were 38.3% and 83.0%, respectively; at the patient level, CR and ORR were 38.3% and 81.9%, respectively. Median index-lesion LTPFS, patient-level LTPFS, PFS, and OS were 19.6, 15.7, 11.1, and 30.5 months, respectively. Low tumor-absorbed dose (TAD) was independently associated with worse OS (adjusted hazard ratio, 2.70; p = 0.016). Twenty-one patients (22.3%) subsequently underwent curative-intent surgery after TARE, with a more favorable OS pattern observed in the postsurgery state in an exploratory time-varying analysis (p = 0.004). Three fatal adverse events occurred.</p><p><strong>Conclusion: </strong>In this single-center retrospective cohort of patients with HCC beyond the Up-to-Seven criteria, favorable tumor control and survival outcomes were observed after TARE, and 22.3% of patients subsequently underwent curative-intent surgery. Higher TAD was associated with longer OS, although this finding should be interpreted cautiously given the potential for confounding. Careful dosimetric planning is warranted given the observed fatal radiation pneumonitis events.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"109108"},"PeriodicalIF":3.1,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Twenty-Three-Year Single Center Experience with Elective Transcatheter Coil Embolization of Unruptured Splenic Artery Aneurysms.","authors":"Ariana C Mills, Rico Pesce, Rahul Patel, Edward Kim, Aaron Fischman, Rajesh Patel, Vivian Bishay, Kirema Garcia-Reyes, Dan Shilo, Jenanan Vairavamurthy, Brett Marinelli, Ageliki Vouyouka, Rami Tadros, Peter Faries, Scott Nowakowski, Michael Marin, Robert Lookstein","doi":"10.1016/j.jvir.2026.109111","DOIUrl":"https://doi.org/10.1016/j.jvir.2026.109111","url":null,"abstract":"<p><strong>Purpose: </strong>To determine the safety and efficacy of elective coil embolization for unruptured splenic artery aneurysms (SAA).</p><p><strong>Materials and methods: </strong>A retrospective review of unruptured SAA treated endovascularly from October 2002 to January 2026 was performed. When the inflow vessel was embolized, primary technical success required both cessation of antegrade flow in the inflow vessel and absence of opacification of the aneurysm sac. When the sac alone was embolized or excluded, primary technical success required absence of sac opacification alone. Risk factors for major splenic infarct were assessed.</p><p><strong>Results: </strong>A total of 156 unique aneurysms were treated in 130 patients. Mean aneurysm size was 2.4 ± 1.1 cm. Primary technical success was achieved in all but one (0.8%) patient over a mean follow-up of 4.1 ± 5.0 years. Secondary technical success was 100% and freedom from sac opacification was 95.1%. Reintervention was required in 4/122 (3.3%) patients with follow-up imaging, all of whom remained successfully treated. Major splenic infarct occurred in 17/122 (13.9%) patients, with portal hypertension as the only independent risk factor for major splenic infarct (adjusted OR 6.07; 95% CI 1.90-19.35; p = 0.002). Eight (6.2%) mortalities occurred, one (0.8%) within 30 days, all unrelated to SAA embolization.</p><p><strong>Conclusion: </strong>Elective coil embolization is a safe and effective treatment for SAA with robust rates of technical success, freedom from rupture, and freedom from sac enlargement.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"109111"},"PeriodicalIF":3.1,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory Chronic Lymphocytic Leukemia Successfully Bridged to CAR T-Cell Therapy Using Splenic Radioembolization.","authors":"Bela Kis, Will Gibbons, Julio Chavez, Javier Pinilla-Ibarz","doi":"10.1016/j.jvir.2026.109107","DOIUrl":"https://doi.org/10.1016/j.jvir.2026.109107","url":null,"abstract":"","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":"109107"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149117343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}